Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 9/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | COMT | P21964 | 4/20 | 0.54 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.47 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.47 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1447258 | 1.00 | FTO (0.60) | FTOMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL3589543 | 0.85 | FTO (0.71) | FTOMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL3589548 | 0.85 | FTO (0.71) | FTOMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL1447413 | 0.80 | FTO (0.55) | FTOMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL1446335 | 0.80 | FTO (0.55) | FTOMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL1446338 | 0.80 | FTO (0.55) | FTOMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL1447414 | 0.80 | FTO (0.55) | FTOMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL20100847 | 0.79 | FTO (0.73) | FTOMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL1446733 | 0.79 | FTO (0.54) | FTOMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL1446730 | 0.79 | FTO (0.54) | FTOMEN1KMT2AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220388999-A1 | NITROCATECHOL DERIVATIVES AS COMT INHIBITORS | BIAL PORTELA & CA SA (PT) | 2022-12-08 | — | — | US | disclosed |
| US-20200102295-A1 | NITROCATECHOL DERIVATIVES AS COMT INHIBITORS | BIAL - PORTELA & CA, S.A. (PT) | 2020-04-02 | — | — | US | disclosed |
| US-10336740-B2 | Nitrocatechol derivatives as COMT inhibitors | BIAL—PORTELA & CA, S.A. (PT) | 2019-07-02 | — | — | US | disclosed |
| US-20170362213-A1 | NITROCATECHOL DERIVATIVES AS COMT INHIBITORS | PORTELA & COMPANHIA, S.A. (PT) | 2017-12-21 | — | — | US | disclosed |
| US-9550759-B2 | Nitrocatechol derivatives as COMT inhibitors | BIAL—PORTELA & CA, S.A. (PT) | 2017-01-24 | — | — | US | disclosed |
| EP-1907382-B1 | NITROCATECHOL DERIVATIVES AS COMT INHIBITORS | BIAL PORTELA & CA SA (PT) | 2015-05-27 | — | — | EP | disclosed |
| US-20150072977-A1 | NITROCATECHOL DERIVATIVES AS COMT INHIBITORS | BIAL - PORTELA & CA, S.A. (PT) | 2015-03-12 | — | — | US | disclosed |
| US-8907099-B2 | Nitrocatechol derivatives as COMT inhibitors | BIAL-PORTELA & CA, S.A. (PT) | 2014-12-09 | — | — | US | disclosed |
| US-20120196904-A1 | NITROCATECHOL DERIVATIVES AS COMT INHIBITORS | PORTELA & CA., S.A. (PT) | 2012-08-02 | — | — | US | disclosed |
| US-8168793-B2 | Nitrocatechol derivatives as COMT inhibitors | PORTELA & CA., S.A. (PT) | 2012-05-01 | — | — | US | disclosed |
| EP-2301934-A1 | Nitrocatechol derivatives as COMT inhibitors | BIAL - Portela & Ca., S.A. (PT) | 2011-03-30 | — | — | EP | disclosed |
| US-20090054437-A1 | Nitrocatechol Derivatives as Comt Inhibitors | PORTELA & CA., S.A. (PT) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362213-A1 | NITROCATECHOL DERIVATIVES AS COMT INHIBITORS | COMT, PNMT, OPRK1 | FTO 556/4885MEN1 4380/4885KMT2A 1728/4885 |
| US-20150072977-A1 | NITROCATECHOL DERIVATIVES AS COMT INHIBITORS | COMT, PNMT, OPRK1 | FTO 556/4885MEN1 4380/4885KMT2A 1728/4885 |
| US-20220388999-A1 | NITROCATECHOL DERIVATIVES AS COMT INHIBITORS | COMT, PNMT, OPRK1 | FTO 605/4885MEN1 4353/4885KMT2A 1796/4885 |
| US-20090054437-A1 | Nitrocatechol Derivatives as Comt Inhibitors | COMT, PNMT, OPRK1 | FTO 556/4885MEN1 4380/4885KMT2A 1728/4885 |
| US-10336740-B2 | Nitrocatechol derivatives as COMT inhibitors | COMT, PNMT, OPRK1 | FTO 556/4885MEN1 4380/4885KMT2A 1728/4885 |
| US-20200102295-A1 | NITROCATECHOL DERIVATIVES AS COMT INHIBITORS | COMT, PNMT, OPRK1 | FTO 605/4885MEN1 4353/4885KMT2A 1796/4885 |
| US-20120196904-A1 | NITROCATECHOL DERIVATIVES AS COMT INHIBITORS | COMT, PNMT, OPRK1 | FTO 556/4885MEN1 4380/4885KMT2A 1728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.